Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P62945

UPID:
RL41_HUMAN

ALTERNATIVE NAMES:
60S ribosomal protein L41; HG12

ALTERNATIVE UPACC:
P62945; A6NG21; P28751

BACKGROUND:
The protein Large ribosomal subunit protein eL41, with alternative names 60S ribosomal protein L41 and HG12, is integral to the ribosome's large subunit, facilitating protein synthesis. It also plays a role in cellular growth processes by interacting with protein kinase CKII, stimulating the phosphorylation of DNA topoisomerase II alpha. This interaction is crucial for DNA replication and cell cycle progression.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Large ribosomal subunit protein eL41 offers a pathway to novel therapeutic approaches. Given its critical role in protein synthesis and cell division, targeting this protein could lead to innovative treatments for diseases caused by dysregulated cellular proliferation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.